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AlgorithmAbstract Introduction: Most adrenal gland lesions are detected by CT; however some patients are
referred for MRI and PET CT, with percutaneous biopsy as the last resort.
Aim of study: To provide the role of various imaging modalities for optimal assessment of adrenal
masses. Furthermore we would like to recommend a diagnostic algorithm.
Patient & methods: We studied 29 patients with 29 adrenal masses (11 adenomas, 6 metastases, 5
myelolipomas, 4 adrenocortical carcinomas, 2 pheochromocytoma & 1 cyst). CT scan was done
with a dedicated adrenal CT protocol. Washout characteristics were then assessed. MRI was done
in 19 patients. Qualitative assessment of the chemical shift images was done in 11 patients. Five
patients underwent PET and PET CT.
Results: In CT: a mean absolute percentage washout of 83% and 41.4% while a mean relative per-
centage washout of 57.4% and 17.95% were found for adenomas and metastases respectively. In
MRI: adenomas showed signal drop on out of phase sequences compared to in phase sequences
while metastases did not. In PET CT: mean maximum SUV uptake for adrenal metastases was
7.5 compared to 2.1 in adenoma.
Conclusion: Our results conﬁrm the evolving role of CT in detection and characterization of an
adrenal mass. Further assessment by MRI & PET CT can be beneﬁcial.
 2015 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Characterization of adrenal masses is essential because the nat-
ure of the mass may have a profound effect on patient’s care.
Also accurate characterization is important for identifying both
malignant & benign lesions, because it would obviate both per-
cutaneous biopsy & repeated interval follow-up imaging (1).Tumors in the adrenal glands are common in humans,
being present in 3% of autopsies performed in persons older
than 50 years (2).
Primary tumors in the adrenals can be hyperfunctioning
(producing excess hormones from the cortex or the medulla
and accompanied by clinical symptoms) or nonfunctioning (3).
Adrenal lesions are often discovered incidentally at examin-
ations performed for other purposes (4).
In patients without a known extra adrenal primary malig-
nancy, most of these lesions are benign nonhyperfunctioning
adenomas. Even in patients with a primary neoplasm, in whom
an adrenal metastasis is an important consideration, most
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common site for metastatic disease. Virtually any primary
malignancy can spread to the adrenals. Lymphoma and carci-
noma of the lung and breast account for a large proportion of
adrenal metastases. Other primary cancers include melanoma,
leukemia, kidney & ovarian carcinoma (5).
Large adrenalmasses are often detectedwith abdominal ultra-
sound, however US depends to a large extent on operator skills.
Furthermore, obesity and overlying gas are obstacles for the visu-
alization of the adrenal glands. Not surprisingly, US does not
detect adrenal masses with the same sensitivity as CT orMRI (5).
The cornerstone of adrenal imaging is CT, performed
before and after intravenous injection of contrast material
and acquired as 3–5 mm scans through the adrenal glands.
The advent of multidetector CT (MDCT) has allowed postpro-
cessing of the acquired data to narrow slice intervals and pro-
vides detailed reformatted images in any plane (6).
Magnetic resonance imaging of the adrenal glands can help
characterizing lesions not properly assessed with CT. Multi-
planar MRI allows precise localization and separation of adre-
nal masses from the surrounding structures, particularly the
liver, spleen, stomach, pancreas and kidneys (3,6).
Generally, the ratio between the signal drop-off from T1-
weighted in-phase to opposed-phase images of the adrenal
mass and various organs including spleen, fat, liver, and mus-
cle has been tested to distinguish between benign and malig-
nant masses. If the adrenal mass-reference organ-ratio, the
ratio between signal intensities of the adrenal mass and the
internal standard (such as the spleen) is less than 70, the lesion
is regarded as benign (5).
Radionuclide imaging is usually a second line test to clarify
equivocal, inconclusive or unexpected results from anatomical
imaging. Scintigraphy of both adrenal medulla and adrenal
cortex is used to demonstrate the functional status of adrenal
nodules or masses shown on anatomical imaging, to detect
extraadrenal ectopic sites of hormone production and to detect
recurrence after surgery (7).
Transcutaneous needle biopsy or FNA of adrenal mass has
been advocated for the investigation of incidentally discovered
adrenal masses. The biopsy is generally performed under either
CT or US guidance. FNA may be helpful in the diagnostic
evaluation of patients with a history of malignancy and those
with a suspicious adrenal mass on imaging. Importantly, to
prevent a potentially life-threatening hypertensive crisis,
FNA should not be attempted before exclusion of pheochro-
mocytoma by endocrine testing (5).
Adrenal imaging complements and assists the clinical and
hormonal evaluation of adrenal tumors. It is important to
reach a protocol to study the clinically suspected suprarenal
masses as well as the incidentalomas.
2. Aim of the study
The aim of our study was to provide the role of various imag-
ing modalities for optimal assessment of adrenal masses. Fur-
thermore we would like to recommend a diagnostic algorithm.
3. Patients & methods
A total of 29 patients (18 males, 11 females; age range 19–
70 years old; mean age 42.9) with 29 adrenal masses werestudied in this prospective study. Most cases were referred to
us from the urology and internal medicine departments in
our hospital and 7 patients had their investigations done in a
private hospitals (5 out of them had undergone PET and
PET CT and 2 patients having neoplastic disease had under-
gone previous CT scan outside our institution).
Adrenal masses were found incidentally on abdominal
sonography or CT done for nonadrenal related complaints
(Figs. 1 and 2) such as abdominal pain, heaviness, mass, vom-
iting and loss of weight in 17 patients as well as during exam-
ination for an extra adrenal primary malignant tumor in 6
patients (1 brain tumor, 1 colonic cancer, 2 breast carcinoma
and 2 bronchogenic carcinoma). Other inclusion criteria were
adrenal masses found during the workup for endocrine and
clinical manifestations raising the suspicion of adrenal affec-
tion: Two patients had clinical and biochemical evidence of
Conn’s syndrome (Fig. 3) such as hypertension, headache,
muscle weakness and hypokalemia, elevated plasma aldoste-
rone and suppressed plasma renin activity. Two other patients
had paroxysmal attacks of hypertension and elevated urinary
24 h VMA. In one patient with known bronchogenic carci-
noma and adrenal deposit (Fig. 4), follow-up and further
assessment of this adrenal lesion was done.
3.1. Protocol of examination
Whenever an incidentaloma was detected usually by CT done
with contrast or US, we were ﬁrst inquired about possible lab-
oratory biochemical abnormalities to exclude the presence of a
hyperfunctioning adrenal lesion including the following:
– serum cortisol level, 1 mg dexamethasone suppression test,
– urine 24 h VMA, serum aldosterone and plasma renin
activity,
– serum electrolytes including Na and K, complete blood
count and liver function tests.
Then we asked about the availability of previous imaging
studies for comparison in order to assess the course of the
lesion over time. The next step was asking about a known his-
tory of primary extra adrenal malignancy.
The ﬁrst imaging modality done was CT scan of the abdo-
men. However one patient did an abdominal US ﬁrst. CT
imaging was performed with a multidetector row helical CT
scanner 4-MDCT scanner (Light Speed, GE Medical System,
Milwaukee – USA). Imaging parameters included section col-
limation of 3–5 mm, high-quality mode, table speed of 7.5 mm/
s, 50% overlap reconstruction, 120 kV and 280–380 mA.
Initially unenhanced images were obtained. Then 120 ml of
contrast medium was injected intravenously. Biphasic contrast
enhanced images were obtained after 75 s (portal venous
phase) and delayed images were ﬁnally obtained after 10 min
from the time of injection.
3.2. Postprocessing calculations
Average attenuation values in HU on the pre-contrast (preat-
tenuation PA), contrast enhanced (early attenuation EA) and
delayed contrast enhanced (delayed attenuation DA) images
were recorded. A circular region of interest ROI was placed
in the center of the adrenal mass on the section on which the
Fig. 1 Right adrenal mass lesion displaying heterogeneous T1 signal with areas of necrosis (a). On T2 images the lesion displayed a
heterogeneous signal as well as large areas of necrosis/cystic degeneration displaying a bright signal (b and c). MRV coronal images (d)
showed some splaying of adjacent renal and hepatic veins without deﬁnite invasion. Gross specimen showing the removed adrenal mass
(e), histopathology revealed a well encapsulated adrenal adenoma with cellular atypia, areas of hemorrhage and necrosis DIAGNOSIS:
Right nonfunctioning atypical Adrenal Adenoma.
Optimal diagnosis of adrenal masses 513mass appeared largest. The ROI covered approximately half to
two-thirds of the mass. Then absolute and relative percentage
washouts (APW, RPW) were calculated as follows:
APW ¼ ½ðEADAÞ=ðEA PAÞ  100 and RPW
¼ ½ðEADAÞ=EA  100 ð8Þ
Following CT examinations patients, with lesions consid-
ered to be benign were advised to come for a single follow-
up CT after 6 months. However, only one patient did return.
Further conﬁrmation was done by MRI examination using
chemical shift protocols as well as fat saturation sequences.
Speciﬁc clues such as the presence of fat or water contents
enabled us to make a ready diagnosis of adrenal myelolipoma
and cyst respectively.
MRI:MR imaging was performed with a 1.5 T unit (Philips
Gyroscan Intera, Netherlands) with a phased-array body coil
in 18 patients. T1-weighted spin echo axial images were
obtained with a TR of 425 ms and a TE of 15 ms. T2 weighted
axial and coronal images were obtained with the fast spin echo
technique by using a TR of 1800 ms and a TE of 100 ms. The
section thickness was 4 mm with an intersection gap of 0.4 mm
for both T1 and T2 weighted imaging. The matrix size was
204 · 256. Respiratory gating was used for spin echo imaging
with ﬂow compensation being used for most of the spin echo
images.
Fat saturation was used for the T2 weighted fast spin
echo images in 4 patients. Chemical shift imaging was per-
formed using a T1-weighted gradient recalled echo sequence
with breath-holding with a TR of 68–160 ms and a TE of
4.9 ms for in-phase images and a TE of 6.3 ms foropposed-phase images. The ﬂip angle was 30, the matrix
size was 128 · 256 and the ﬁeld of view varied from 320
to 375 cm. Qualitative assessment of the chemical shift
images was done to determine whether signiﬁcant drop of
signal had occurred in the lesion on the opposed-phase
images relative to the in-phase images.
Five patients underwent PET and PET CT investigations
as part of their metastatic workup for a known primary extra
adrenal malignancy: Examination was conducted on a spiral
64 MSCT scan. Before undergoing PET CT, patients fasted
for at least 6 h, although oral hydration with glucose-free
water was allowed. After a normal blood glucose level in
peripheral blood has been ensured, patients received an intra-
venous injection of 370 MBq (10 mCi) of FDG and then rested
for about 45 min before undergoing scanning. Scans were
acquired with a PET scanner combined with a multisection
64 CT scanner GE discovery VCT. The axes of the two systems
were mechanically aligned such that the patient could be
moved from the CT to the PET gantry by moving the exami-
nation table. CT without contrast was performed from the
head to the pelvic ﬂoor according to a standardized protocol.
Patients maintained normal shallow respiration during CT,
and immediately afterward, PET was performed with the iden-
tical transverse ﬁeld of view. Acquisition time for PET was
5 min per table position (each frame). The CT data were
resized from a 512 · 512 matrix to a 128 · 128 matrix to match
the PET data so that scans could be fused and CT-based trans-
mission maps generated. PET data sets were reconstructed iter-
atively using an ordered subset expectation maximization
algorithm with segmented attenuation correction. Co-regis-
Fig. 2 Right adrenal mass lesion. Longitudinal US section through the liver (a) shows a well deﬁned rounded echogenic mass seen
arising from the body of the right adrenal gland. On CT scan (b), the lesion appears as a typical well encapsulated heterogeneous supra-
renal mass of low density with negative attenuation values. MRI (c and d) conﬁrmed the fatty nature of the lesion that depicted bright T1
and T2 signal. DIAGNOSIS: Right benign nonfunctioning, nonhemorrhagic Adrenal Myelolipoma.
Fig. 3 Adrenal CT protocol: well deﬁned small homogeneous right adrenal mass (a–c). PA: 6, EA: 20.7, DA: 5.8, APW: 101%, RPW:
71.9%. CS MRI: T2 WI (d), in phase (e) and out of phase (f) show marked signal drop DIAGNOSIS: Conn’s syndrome due to Right
adrenal adenoma.
514 S. Hanna et al.tered scans were then displayed on a workstation with com-
mercially available software. PET ﬁndings were interpreted
as positive if the FDG uptake in an adrenal lesion was greater
than or equal to that in the liver and as negative if lesion
uptake was less than that in the liver.In the two patients with clinical and biochemical evidence
pointing to Conn’s syndrome, a dedicated adrenal CT protocol
was the appropriate next step. Further chemical shift MRI was
also done for both conﬁrmation of diagnosis and illustration
purposes. In the two patients with clinical and biochemical evi-
Fig. 4 Fused PET-CT images (a and b) also showed intense homogeneous uptake by the right adrenal nodule, ﬁndings consistent with a
malignant lesion. Coronal, sagittal and axial fused PET-CT images (c–e) show intense tracer uptake in the right adrenal nodule SUV> 3
DIAGNOSIS: Stationary course.
Bar graph 1 Bar graph showing the distribution of adrenal
masses by diagnosis.
Optimal diagnosis of adrenal masses 515dence pointing to a pheochromocytoma CECT of the abdo-
men was done for localization, followed by MRI. One patient
also underwent MIBG scan for conﬁrmation as well as for the
detection of possible extra adrenal uptake and metastases.
131I-MIBG was used; a dose of 1 mCi was given intravenously
to the patient and imaging was done after 24 and 72 h. Ante-
rior and posterior whole body scans were obtained as well as
spot planar images. We made sure that the patient was off
any sympathomimetics and alpha blockers 1 week prior to
the examination.
4. Results
A total of 29 patients with 29 adrenal masses were included in
our study. Adrenal masses encountered included 11 adenomas,
6 metastatic deposits, 5 myelolipomas, 4 adrenocortical carci-
nomas, 2 pheochromocytomas, and one case of adrenal cyst
(Bar graph 1).
Scenarios by which adrenal masses were encountered
included the following:
I. In four patients clinical and laboratory evidence of
endocrine and hormonal abnormalities were found and
prompted the search for adrenal pathology.
II. In twenty-four patients adrenal lesions were found inci-
dentally on examinations done for other complaints,
including metastatic workup (Incidentalomas).
III. In one patient with known bronchogenic carcinoma, fol-
low-up for a previously detected adrenal metastases was
required.
Distribution of incidentalomas by diagnosis: 9 adenomas, 5
metastases, 5 myelolipomas, 4 ACC and 1 cyst (Bar graph 2).Eight cases were pathologically proven: 4 cases of ACC, 2
cases of pheochromocytoma, 1 case of myelolipoma and one
case of atypical adenoma. The diagnosis of all the other cases
relied upon clinical and imaging ﬁndings.
4.1. Results of CT study
1. Patients with a ﬁnal diagnosis of adenoma had a dedicated
adrenal CT protocol. In the Pre-contrast study: 8 patients
had lesions with pre-attenuation value less than 10 HU
and 3 patients had lesions with pre-attenuation (PA) value
greater than 10 HU.The mean delayed attenuation value on CECT for ade-
noma was 11.8 HU.
The calculated mean APW for adenoma was 83%.
The calculated mean RPW for adenoma was 57.4%.
2. Patients with a ﬁnal diagnosis of adrenal metastases showed
the following CT ﬁndings:The mean PA value for adrenal metastases was 38.3 HU.
Bar graph 2 Bar graph showing the distribution of incidentalo-
mas by diagnosis.
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The mean DA value for adrenal metastases was 54.35
HU.
The calculated mean APW for metastases was 41.4%.
The calculated mean RPW for metastases was 17.95%.
3. Bar graph 3 shows evidence of marked differences in both
APW and RPW characteristics between adenomas and
metastases with adenomas showing more rapid washout
on dynamic and delayed contrast enhanced CT than
metastases.Mean APW for adenoma was 83%.
Mean RPW for adenoma was 57.4%.
Mean APW for metastases was 41.4%.
Mean RPW for metastases was 17.95%.
4.2. Results of MRI study
MRI study was done in 19 patients with the chemical shift
(CSI) protocol applied whenever distinction between adrenal
adenoma and metastases was required (done in 11 patients).
Adenomas showed signal drop on out of phase sequences com-
pared to in phase sequences while metastases did not. A fat-
saturation sequence was applied when the diagnosis of myelo-
lipoma was suspected.
Contrast administration was done in two patients (one with
a ﬁnal diagnosis of pheochromocytoma and one with a ﬁnal
diagnosis of ACC).
4.3. Results of PET and PETCT study
Five patients underwent PET and PET CT study:Bar graph 3 Bar graph showing the difference between the APW
and RPW characteristics between adenomas & metastasis.Bar graph 4 shows evidence of marked differences in both
APW and RPW characteristics between adenomas and metas-
tases with adenomas showing more rapid washout on dynamic
and delayed contrast enhanced CT than metastases.
Mean APW for adenoma was 83%.
Mean RPW for adenoma was 57.4%.
Mean APW for metastases was 41.4%.
Mean RPW for metastases was 17.95%.
Adrenal metastases showed intense focal tracer uptake
greater than that of the liver. The mean maximum SUV uptake
for adrenal metastases was 7.5.
On the other hand minimal uptake lower than hepatic
uptake was noted in the adrenal adenoma. The maximum
SUV uptake for the adrenal adenoma was 2.1.
5. Discussion
In our study we had 29 patients with adrenal masses, each
patient had unilateral pathology and the adrenal masses
encountered included 11 adenomas, 6 metastatic deposits, 5
myelolipomas, 4 adrenocortical carcinomas, 2 pheochromocy-
tomas, and one case of adrenal cyst. Adenoma was by far the
commonest encountered lesion.
These ﬁndings are comparable with previous studies. In a
study conducted by Maurea et al. (9) on 36 patients with adre-
nal masses (uni and bilateral) a total of 41 lesions were evalu-
ated with the largest proportion being adenomas (29) followed
by 5 pheochromocytomas, 3 cysts, 2 adrenocortical carcino-
mas and 2 metastatic deposits.
Before the advent of contemporary cross-sectional imaging,
the diagnosis of many of these diseases remained elusive, often
only to be discovered at autopsy (10).
When a pheochromocytoma is suspected on clinical and
laboratory grounds, CT is the study of choice to conﬁrm the
diagnosis. Typically, an adrenal mass is identiﬁed at CT.
Three-dimensional imaging and coronal reconstructions may
be helpful to demonstrate adjacent vessels, particularly with
the recent advent of laparoscopic adrenalectomy. If an adrenal
mass is identiﬁed at CT in a patient with a suspected pheochro-
mocytoma, the treatment is surgical resection. If an adrenal
mass is not seen, attention should be directed to the paraspin-Bar graph 4 Bar graph showing the distribution of adrenal
lesions by PET-CT.
Optimal diagnosis of adrenal masses 517ous region because 10% of pheochromocytomas are extraadre-
nal. Paraganglioma is the preferred term for such tumors,
rather than extraadrenal pheochromocytoma (11).
The MR imaging appearance of a pheochromocytoma has
typically been described as T2 hyperintense; however, not all
pheochromocytomas have this imaging characteristic (11).
For patients in whom a pheochromocytoma is suspected
and an adrenal mass is not identiﬁed at CT or MR imaging,
nuclear medicine imaging using I-131 MIBG can be used for
the detection of metastases since it allows whole body
imaging.
In our study we had one case of pheochromocytoma that
displayed slightly heterogeneous low T1 signal and a low T2
signal with some areas of cystic degeneration, lacking the com-
monly described light bulb appearance on T2 images. This
patient underwent an MIBG scan that showed prolonged
increased uptake within the adrenal lesion that was conﬁrmed
to be a hyperfunctioning pheochromocytoma on pathological
examination. No extra adrenal uptake or metastases could
be detected.
Pheochromocytomas whether benign or malignant might
accumulate FDG, the uptake being greater for malignant
lesions (11).
Shulkin et al. (12) compared FDG PET with MIBG and
found sensitivity of 83% for the detection of benign pheochro-
mocytoma for MIBG compared to 58% for FDG PET. For
malignant pheochromocytomas, MIBG had sensitivity of
88%, whereas FDG PET had sensitivity of 82%. Although
MIBG had better sensitivity, all of the MIBG negative lesions
showed avid FDG uptake. These authors concluded that most
pheochromocytomas accumulate FDG so FDG PET may be
especially useful in deﬁning the distribution of those pheochro-
mocytomas that fail to concentrate MIBG (13).
Primary hyperaldosteronism is characterized clinically by
hypertension and hypokalemia. The cause is an adrenal ade-
noma in about 80% of patients and adrenal gland hyperplasia
in 20%. Adrenal carcinoma is an extremely rare cause of pri-
mary aldosteronism (11).
After the diagnosis of hyperaldosteronism has been estab-
lished through clinical and laboratory tests, a dedicated CT
study of the adrenal gland performed with thin (3-mm) colli-
mation is usually the ﬁrst-line imaging examination. Adrenal
adenomas are often small and difﬁcult to detect, since over
20% are less than 1 cm in diameter (11).
In our study two patients presented with evidence of hypo-
kalemia, hyperaldosteronism and suppressed plasma renin
activity establishing a clinical and biochemical diagnosis of
Conn’s syndrome. On CT examination small lipid rich adrenal
adenomas were found.
In the majority of our patient population (twenty-four
patients), a mass in the adrenal gland was identiﬁed on an
US, CT or MRI scan of the abdomen that has been performed
for another indication, a ﬁnding compatible with previous
investigations.
Such lesions known as adrenal incidentalomas are present in
up to 10% of the adult population and the prevalence increases
with age. They have been the concern of much recent debate
with regard to their diagnostic approach (11,14).
In the literature the most common incidentaloma remains
adenoma. Others include pheochromocytoma, myelolipoma,
ganglioneuroma, cysts, hematomas, ACC, metastases and
other rare entities (12). In our study the distribution of inciden-talomas was as follows: 9 adenomas, 5 metastases, 5 myelo-
lipomas, 4 ACCs and one cyst.
Unfortunately, most of these lesions, whether benign or
malignant, functioning or nonfunctioning appear similar when
detected. Fortunately, however most will prove to be benign.
This fact becomes even more deﬁnitive when the patient has
no history of malignancy. Song et al. (15) showed that not a
single lesion in 1049 lesions in patients without any history
of malignancy turned out to be malignant.
However, if the patient has a known underlying extraadre-
nal malignancy, up to 50% of detected adrenal masses in these
patients will be malignant and mostly metastatic (16).
In our study only 4 patients with no known history of
malignancy had malignant incidentally discovered adrenal
lesions proven to be ACC on histopathological examination.
Their radiological morphological features were highly sugges-
tive of malignancy including large size, areas of necrosis, cystic
degeneration and also calciﬁcation. One patient with known
breast cancer had an incidentally discovered adrenal lesion
that showed no signiﬁcant tracer uptake on PET CT and
was diagnosed as an adenoma. In the remaining patients with
no known malignancy and incidentally discovered adrenal
lesions, the ﬁndings were those of benignity.
In our study the presence of macroscopic fat was a clue to a
myelolipoma diagnosis, and water attenuation contents to a
diagnosis of adrenal cyst. One patient however presented with
a very large heterogeneous adrenal mass with necrosis and
hemorrhage that raised our suspicion for malignancy but even-
tually proved to be an atypical hemorrhagic adenoma on his-
topathological examination.
In our study we were systematically inquired about hor-
monal proﬁles suspicious for endocrine abnormalities in all
cases of incidentalomas. None of them however had evidence
of hyperfunction. A limitation, however is the rather small
number of our patient population.
By whatever imaging method the incidentaloma is detected
(the majority will be by CT), a 6 month follow-up CT is recom-
mended to ensure lesion stability to conﬁrm benign disease.
Any lesion growth is suspicious for malignant disease. Rarely
benign adenomas can grow a few millimeters in this time
frame, but it is extremely unlikely. Other benign lesions that
may show growth are hematomas or myelolipomas, particu-
larly if the latter hemorrhage. Fortunately both of these lesions
are readily diagnosed by unenhanced CT because hematomas
are hyperattenuating and most myelolipomas show macro-
scopic fat (13).
Most concerning is growth in an ACC, although many of
these are larger than 4 cm by the time they present (13).
Follow-up was a major limitation in our study as patients
diagnosed with a most certain benign disease did not return
for a follow-up examination. Only one of our patients diag-
nosed with a small myelolipoma came 8 months later for CT
urinary tract study to investigate renal stones. The CT revealed
no appreciable changes in the previously detected adrenal
lesion.
Therefore imaging is indeed central to the diagnosis of an
adrenal incidentaloma. Several techniques are available for
characterization, each having merits and weaknesses (10).
Most incidental adrenal lesions are detected by CT, usually
CECT (without dedicated adrenal protocol delayed imaging).
Most benign and malignant lesions show variable enhance-
ment on dynamic CECT and can rarely be characterized by
518 S. Hanna et al.this test alone. As we mentioned before there could be some
imaging clues that permit early characterization (signiﬁcant
interval growth, large size, markedly irregular lesion, some-
times calciﬁcation), but the macroscopic features for the
majority of lesions will not permit an easy diagnosis (10).
A few may be conﬁdently assigned as benign which was the
case in our study for adrenal cyst and myelolipomas for
instance.
On the other hand, it has been known for almost two dec-
ades that unenhanced CT can prove very useful in differentiat-
ing benign from malignant disease (10).
Unenhanced CT takes advantage of the fact that around
70% of adrenal adenomas contain signiﬁcant intracellular lipid
(mainly cholesterol, fatty acids and neutral fat), in contrast to
almost all malignant lesions that do not. The high intracellular
lipid content lowers the unenhanced CT density of most ade-
nomas (10).
Lee et al. (17) found that the mean attenuation of adeno-
mas (2.2 HU) was signiﬁcantly lower than that of nonadeno-
mas (28.9 HU). By using a threshold of 0 HU, these lesions
could be then differentiated with sensitivity and speciﬁcity of
47% and 100%, respectively. Later Korobkin et al. (18)
showed that there is an inverse linear relationship between
fat concentration and attenuation on unenhanced CT images.
A meta-analysis of published studies later found that if the CT
attenuation threshold is raised to 10 HU, the test sensitivity
becomes far higher (71%) while high speciﬁcity (98%) is main-
tained. In clinical practice therefore, 10 HU is the most widely
used threshold value for the diagnosis of a lipid rich adrenal
adenoma (13).
In our study the mean attenuation of adenomas on NECT
was 8.85 HU. Eight patients had a NECT attenuation less than
10 HU and 3 patients had an attenuation greater than 10 HU
indicating lipid poor adenomas.
Song et al. (15) have shown that in 973 consecutive patients
with 1049 incidental adrenal masses adenomas accounted for
75% of incidental masses, of which 78% were lipid rich adeno-
mas with native CT attenuation values of less than 10 HU.
Furthermore, up to 30% of adenomas are lipid poor and
have an attenuation value greater than 10 HU on unenhanced
CT scans, as do almost all malignant lesions. In our study two
lesions that proved to be adenomas on further investigations
had an attenuation value greater than 10 HU on NECT.
Therefore, lesions with a precontrast attenuation greater
than 10 HU require further evaluation to characterize them
(13).
Several authors reported that although the CT densitome-
try method was unable to characterize adrenal lesions during
the dynamic phase of a CECT, delayed CECT on the other
hand particularly when evaluated in conjunction with the
dynamic study, does enable characterization of most lipid rich
and lipid poor adrenal lesions. This is fortuitous because
almost all adrenal lesions can now be differentiated by CT,
which is faster, cheaper and more available than MRI. Modern
multidetector CT dose reduction programs render the test suit-
able for most patients with indeterminate adrenal incidentalo-
mas (10).
Korobkin et al. (18) showed that circulating contrast mate-
rial within the adrenal gland tended to washout from ade-
nomatous lesions far quicker than nonadenomatous lesions,
particularly malignant ones. If attenuation measurements of
the adrenal gland were made on images performed 15 min afterthe dynamic CECT, an attenuation threshold could be found
that could again differentiate benign from malignant lesions.
He also showed that if one were to calculate the fraction of
contrast material that washed out of the adrenal gland from
the dynamic to the delayed CECT, it would be possible to
characterize most, if not all, adenomatous lesions. If lesions
showed an absolute contrast-enhanced percentage washout
of greater than 60%, then lesions can be conﬁdently assumed
to be benign. A relative contrast-enhanced percentage washout
can also be calculated, and a value of 40% or greater has been
used with similar accuracy. Lesions showing an absolute con-
trast enhanced percentage washout and relative contrast
enhanced percentage washout of less than 60% and 40%,
respectively, are consistent with nonadenomatous lesions, usu-
ally metastases (10).
Other authors have also conﬁrmed the test accuracy using
10 min delayed CECT in an attempt to address busy CT sched-
ules. Sensitivity of 100% and speciﬁcity of 98% have been
obtained for a threshold APW value of 52% and a threshold
RPW value of 38–40% (13).
In our study the 10 min delayed protocol was employed and
a threshold APW mean value of 83% and RPW of 57.4% was
found for adenomas. As for metastases a threshold APWmean
value of 41.4% and RPW of 17.95% was found.
So, in general, a combination of unenhanced CT, contrast
enhancement and washout characteristics correctly discrimi-
nates nearly all adrenal adenomas from malignant lesions (13).
MRI: with its inherent tissue characterization ability, it
offers utility in the assessment of adrenal incidentalomas.
Some believe that the next appropriate test is chemical shift
MRI. This technique also exploits the presence of abundant
intracellular fat within lipid rich adenomatous lesions. By
intermittently imaging the adrenal gland with variable T1 gra-
dient-recalled echo pulse sequences, it is possible to summate
voxular fat and water signal during in-phase sequences but null
out the signal on opposed-phase sequences for those voxels
with equal quantities of fat and water. Although this signal
drop can be quantiﬁed, simple visual observation of this signal
drop off is sufﬁcient to diagnose most lipid rich adenomas (10).
Similarly in our study cases of adenomas showed signiﬁcant
signal drop on chemical shift MRI out of phase sequences as
opposed to metastases.
Important caveats to be aware, however, are ACC, pheo-
chromocytoma and clear renal cell cancer metastases, all of
which may sometimes show signal loss on out-of phase images
(13).
ACCs are seen as heterogeneous on both T1 and T2
weighted imaging because of hemorrhage and necrosis. Necro-
tic areas can have high signal intensity on T2 weighted imaging
and blood products can result in areas of high signal intensity
within the lesion on T1-weighted imaging.
The sensitivity and speciﬁcity of CSI for the differentiation
of incidental adrenal lesion are similar to those of unenhanced
CT densitometry. Studies have shown that for lipid rich adeno-
mas, there is effectively no difference between CT and MRI,
but CSI might be superior when evaluating lipid poor adeno-
mas (10).
In our study two patients with adenomas had a NECT
attenuation value exceeding 10 HU but show effective signal
drop on chemical shift MRI.
PET CT: So far, tests used to characterize the adrenal inci-
dentaloma have exploited the lipid content and physiological
Optimal diagnosis of adrenal masses 519washout patterns. However the metabolic activity of the adre-
nal gland can also be evaluated with 18F-FDG PET imaging,
which has shown sufﬁcient test accuracy to be clinically useful.
Combined PET CT can assign adrenal tracer uptake to the
location of the adrenal gland when present. Malignancies are
usually more metabolically active than benign neoplasms,
hence the strength of PET to differentiate benign from malig-
nant disease (10).
Adrenal FDG uptake is considered to be of malignant ori-
gin when intensity is higher than hepatic uptake. Blake (8)
found that of 32 benign adrenal masses, 30 showed 18 F-
FDG uptake activity on visual analysis of PET/CT that was
less than that of the liver as well as an SUV less than 3 on
quantitative analysis. Metser et al. (19) found using a maxi-
mum SUV of 3.1 for differentiating malignant from benign
adrenal lesions had sensitivity and speciﬁcity of 98.5% and
92% respectively. When they combined the SUV threshold
with attenuation analysis from unenhanced CT (<10 HU
positive for adenoma) they found sensitivity of 100% and spec-
iﬁcity of 98%.
Although quantitative signal intensity has been used to
good effect, it has also been shown that visual quantitative
analysis is just as effective (10).
In our study four of the patients that underwent PET study
showed focal intense uptake in the adrenal lesions greater than
that of the liver with SUV greater than 3 (the mean maximum
SUV was 7.5) and demonstrated to be metastatic deposits.
Also whole body PET will show any metastatic lesions and
help in the detection of the primary site of malignancy.
However, a minority of benign adrenal lesions can also be
mildly metabolically active as can some malignant lesions.
Thus any lesion showing moderate PET activity should be con-Fig. 5 Proposed algorithm fsidered indeterminate. On the other hand marked activity is
almost always malignant (10).
It can be correctly stated that dedicated PET CT scanners
offer the advantages of both techniques, potentially offering
lesion characterization by their lipid content, washout and
metabolic activity. Although one report did comment that
the combination of an adrenal CT protocol with PET CT data
permits 100% accuracy for adrenal lesion characterization, the
washout CT data were acquired from a separate dedicated
adrenal CT protocol. To date, no study has evaluated adrenal
PET in combination with an adrenal CT protocol (NECT and
dynamic and delayed CECT) at one sitting using a PET/CT
scanner alone, most likely because this test is cumbersome,
not widely available, a signiﬁcant radiation burden to the
patient and expensive (13).
On the other hand, a few adrenal lesions remain uncharac-
terized by CT washout tests or PET, so deﬁnitive imaging
characterization for these remaining lesions would likely neces-
sitate both PET and a dedicated adrenal protocol, ideally per-
formed at the same sitting, of if necessary separately. For now
most institutions do not routinely use PET CT (or PET) as the
primary investigation to characterize adrenal lesions (10).
Adrenal lesions, can for the most part, be characterized by
imaging alone. There may be a few remaining lesions that
remain indeterminate despite prior imaging, lipid sensitive
CT and washout tests and even PET CT. If absolute diagnosis
is required it is reasonable to perform percutaneous biopsy.
On CECT most radiologists are left with indeterminate
lesions that are usually of moderate size (1–3 cm), homoge-
neous and smooth-walled.
Therefore assuming no prior imaging is available as we
have discussed before, then the next suitable test is unenhancedeasible in our department.
520 S. Hanna et al.CT. It should be noted that placement of the ROI for density
measurement is critical for accurate adrenal characterization.
The ROI should be at least one half to two thirds of the adre-
nal surface area, otherwise noise effects from small ROIs will
render the measurement inaccurate (10).
An imaging and clinical algorithm should be applied for use
when confronted with an adrenal incidentaloma. This is a pro-
posed algorithm feasible in our department (Fig 5).
6. Conclusion
MDCT has an evolving role of in detection and characteriza-
tion of an adrenal mass.
A mean absolute percentage washout of 83% and 41.4%
was found in adenomas and metastases respectively while a
mean relative percentage washout of 57.4% and 17.95% was
found for adenomas and metastases respectively, indicating
that adenomas washout contrast more rapidly.
Before embarking on an algorithm that enables differentia-
tion between benignity and malignancy, it should be stressed
that some of the incidentalomas are hyperfunctioning and hor-
mone producing. Therefore it is advised as much as possible
that all patients undergo hormonal testing to exclude hyper-
functioning diseases before other imaging tests are performed.
If negative the next question is to determine whether the
patient has an underlying extra adrenal malignancy. If not
the overwhelming majority of lesions will be benign, most
likely a nonfunctioning adenoma. It is then reasonable to per-
form a single follow-up CT examination at 6 months. The next
question that is asked is whether the patient has undergone any
prior cross-sectional imaging. If a lesion is stable for at least
6 months the likelihood of malignancy is negligible.
If the lesion still remains indeterminate, some might argue
that lipid sensitive MRI might be useful however it only eval-
uates the same physiological factors as unenhanced CT.
PET CT has shown high accuracy in the characterization of
adrenal lesions but as previously discussed is not the ﬁrst line
test. However if performed, most malignant lesions will show
avidity for 18 F-FDG and most benign lesions will not. There
are, however, a number of benign lesions that show mild FDG
avidity, so the test is not absolute. In such circumstances,
lesions are still indeterminate.
If absolute diagnosis is required it is reasonable to perform
percutaneous biopsy, but again, only after evaluating all clin-
ical and imaging data available. However the radiologist can
establish a deﬁnitive diagnosis for most adrenal masses based
on imaging ﬁndings alone following a proper algorithm
encompassing a wide array of highly speciﬁc diagnostic tests.
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